– USA, CA – Janux Therapeutics, Inc. (Nasdaq: JANX), a biopharmaceutical company, today announced the appointment of Winston Kung to its Board of Directors, effective immediately.
“I’d also like to welcome Winston to Janux’s Board. Winston’s operational leadership and his track record of deal-making and financial acumen will be instrumental as we move our lead PSMA T-cell engager into the clinic and bring forward a deep portfolio of other T-cell engagers and immunomodulatory.” said CEO, Dr. David Campbell.
The company also announced that Dr. Stefan Heller resigned from the Board.
About Winston Kung
Winston Kung is currently CFO and COO at PMV Pharma. Prior to joining PMV Pharma, Mr. Kung was a ViP of Business Development and Global Alliances at Celgene and CBO at Celgene Cellular Therapeutics. While at Celgene, he led the strategic long-range plan formation, multiple transactions, equity investments, company integrations, and a team that managed Celgene’s alliance portfolio of more than 100 collaborations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group. He worked on various transactions including public and private financings, mergers, acquisitions, spin-outs, and other financial advisory engagements.
From 2004 to 2007, Mr. Kung served at Amgen as a co-founder of the Alliance Management group and as the deal lead on multiple acquisitions as part of the Corporate Development group. He was also part of the Business and Corporate Development group at Genentech. He worked on several transactions, including leading the spin-out of Tercica (acquired by Ipsen), and co-led the formation of the Genenfund, Genentech’s first Corporate Venture Capital Fund.
“I am excited to join Janux’s Board to help advance the company’s world-class research and emerging pipeline of tumor-activated therapeutics,” said Mr. Kung. “Janux is developing immune engagers and stimulators that could dramatically improve cancer treatment by delivering these molecules more safely and effectively.”
He received his MBA from Harvard Business School and his A.B. in Biology and A.B in International Relations with honors from Brown University.
About Janux Therapeutics
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms to treat better patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers, and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor, and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to enhance the anti-tumor activity of T cells further.
For more information: https://www.januxrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.